Cargando…

The clinical features of retinal disease due to a dominant mutation in RPE65

PURPOSE: To present a detailed phenotypic and molecular study of two families with autosomal dominant RPE65-related retinal dystrophy. METHODS: Five patients from two families were ascertained from the retinal clinics of a tertiary referral center. Phenotyping included retinal imaging and electrophy...

Descripción completa

Detalles Bibliográficos
Autores principales: Hull, Sarah, Mukherjee, Rajarshi, Holder, Graham E., Moore, Anthony T., Webster, Andrew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Vision 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901053/
https://www.ncbi.nlm.nih.gov/pubmed/27307694
_version_ 1782436733929914368
author Hull, Sarah
Mukherjee, Rajarshi
Holder, Graham E.
Moore, Anthony T.
Webster, Andrew R.
author_facet Hull, Sarah
Mukherjee, Rajarshi
Holder, Graham E.
Moore, Anthony T.
Webster, Andrew R.
author_sort Hull, Sarah
collection PubMed
description PURPOSE: To present a detailed phenotypic and molecular study of two families with autosomal dominant RPE65-related retinal dystrophy. METHODS: Five patients from two families were ascertained from the retinal clinics of a tertiary referral center. Phenotyping included retinal imaging and electrophysiological testing. Bidirectional Sanger sequencing of exon 13 of RPE65 and its intron–exon boundaries was performed on all reported patients and segregation confirmed in available relatives. The main outcome measures were the results of an ophthalmic examination and investigation and molecular genetic analysis. RESULTS: Four affected patients from two families presented with nyctalopia and central visual disturbance in adulthood progressing to severe visual loss by the fifth to eighth decades. The patients had extensive chorioretinal atrophy with a relatively preserved anterior retina. In the second family, one patient had bilateral, vitelliform-like foveal lesions consistent with adult onset vitelliform macular dystrophy and no peripheral retinal changes. These unrelated families were both heterozygous for c.1430A>G (p.Asp477Gly). One unaffected family member also tested positive for this mutation but had good vision at age 80 years. CONCLUSIONS: Autosomal dominant retinal dystrophy resembling choroideremia can arise from a heterozygous mutation in RPE65. It may manifest with mild disease or be non-penetrant. Awareness of these unusual presentations can facilitate targeted molecular investigation.
format Online
Article
Text
id pubmed-4901053
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Molecular Vision
record_format MEDLINE/PubMed
spelling pubmed-49010532016-06-15 The clinical features of retinal disease due to a dominant mutation in RPE65 Hull, Sarah Mukherjee, Rajarshi Holder, Graham E. Moore, Anthony T. Webster, Andrew R. Mol Vis Research Article PURPOSE: To present a detailed phenotypic and molecular study of two families with autosomal dominant RPE65-related retinal dystrophy. METHODS: Five patients from two families were ascertained from the retinal clinics of a tertiary referral center. Phenotyping included retinal imaging and electrophysiological testing. Bidirectional Sanger sequencing of exon 13 of RPE65 and its intron–exon boundaries was performed on all reported patients and segregation confirmed in available relatives. The main outcome measures were the results of an ophthalmic examination and investigation and molecular genetic analysis. RESULTS: Four affected patients from two families presented with nyctalopia and central visual disturbance in adulthood progressing to severe visual loss by the fifth to eighth decades. The patients had extensive chorioretinal atrophy with a relatively preserved anterior retina. In the second family, one patient had bilateral, vitelliform-like foveal lesions consistent with adult onset vitelliform macular dystrophy and no peripheral retinal changes. These unrelated families were both heterozygous for c.1430A>G (p.Asp477Gly). One unaffected family member also tested positive for this mutation but had good vision at age 80 years. CONCLUSIONS: Autosomal dominant retinal dystrophy resembling choroideremia can arise from a heterozygous mutation in RPE65. It may manifest with mild disease or be non-penetrant. Awareness of these unusual presentations can facilitate targeted molecular investigation. Molecular Vision 2016-06-10 /pmc/articles/PMC4901053/ /pubmed/27307694 Text en Copyright © 2016 Molecular Vision. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited, used for non-commercial purposes, and is not altered or transformed.
spellingShingle Research Article
Hull, Sarah
Mukherjee, Rajarshi
Holder, Graham E.
Moore, Anthony T.
Webster, Andrew R.
The clinical features of retinal disease due to a dominant mutation in RPE65
title The clinical features of retinal disease due to a dominant mutation in RPE65
title_full The clinical features of retinal disease due to a dominant mutation in RPE65
title_fullStr The clinical features of retinal disease due to a dominant mutation in RPE65
title_full_unstemmed The clinical features of retinal disease due to a dominant mutation in RPE65
title_short The clinical features of retinal disease due to a dominant mutation in RPE65
title_sort clinical features of retinal disease due to a dominant mutation in rpe65
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901053/
https://www.ncbi.nlm.nih.gov/pubmed/27307694
work_keys_str_mv AT hullsarah theclinicalfeaturesofretinaldiseaseduetoadominantmutationinrpe65
AT mukherjeerajarshi theclinicalfeaturesofretinaldiseaseduetoadominantmutationinrpe65
AT holdergrahame theclinicalfeaturesofretinaldiseaseduetoadominantmutationinrpe65
AT mooreanthonyt theclinicalfeaturesofretinaldiseaseduetoadominantmutationinrpe65
AT websterandrewr theclinicalfeaturesofretinaldiseaseduetoadominantmutationinrpe65
AT hullsarah clinicalfeaturesofretinaldiseaseduetoadominantmutationinrpe65
AT mukherjeerajarshi clinicalfeaturesofretinaldiseaseduetoadominantmutationinrpe65
AT holdergrahame clinicalfeaturesofretinaldiseaseduetoadominantmutationinrpe65
AT mooreanthonyt clinicalfeaturesofretinaldiseaseduetoadominantmutationinrpe65
AT websterandrewr clinicalfeaturesofretinaldiseaseduetoadominantmutationinrpe65